Opportunities in Brazil Insurance Market

发布时间：2007.11

价格

Single User PDF Format:$1,000
Multi-User License:$1,600
Hard Copy:$1,300
CD-ROM:$1,300

内容介绍

The RNCOS report on “Opportunities in Brazil Insurance Market” provides extensive research and in-depth analysis on the insurance sector in Brazil. It helps clients to analyze the leading-edge opportunities critical to the success of the insurance industry in the country. Detailed data and analysis helps clients navigate the evolving insurance markets of the region. 

The forecast given in this report is not based on a complex economic model, but is intended as a rough guide to the direction in which the market is likely to move. This forecast is based on a correlation between past market growth and growth of base drivers.

Market Analysis

A large population makes Brazil the biggest potential insurance market in Latin America, ahead of Mexico and Argentina, but despite the rapid growth in the past three years (2004-2006), its population remains underinsured. There is considerable vertical integration between the insurers and the banks. Most of the larger banks, such as Banco Bradesco and Unibanco, offer a full range of insurance services. Insurance companies, like financial institutions, invest heavily in government securities and have little exposure to the volatile equity market.

Driven by a strong rise in purchases of life insurance, which is reflecting strengthening real incomes and increased confidence in macroeconomic stability, the Brazilian insurance market has been expanding rapidly since 2003. Overall, the market remains small, with total premiums accounting for just over 2.8% of GDP in 2006.

Key Findings

§ Brazilian Life and Retirement Savings market, in premium terms, is expected to grow at the compounded rate of 18.89% during 2007-2011.
§ Automobile insurance is anticipated to grow at the compounded rate of 14.16% during 2007-2011, while Health insurance sector is projected to grow at a CAGR of nearly 13% for the period spanning from 2007 to 2011.
§ Homeowner insurance is projected to grow at the CAGR of nearly 14% from 2007 to 2011, mainly due to continuous declining interest rates in Brazil.
§ Of the total premium income, general insurance accounted for almost one-half and  automobile insurance accounted for one-third total premium income in 2005.
§ There are ample opportunities for the IT sector as total spending on this sector by insurance sector is projected to grow at the compounded rate of 14.42% during 2007-2011.
§ The liberalization of reinsurance market will lead to rise in FDI.
§ Brazilian insurers prefer mutual funds as investment instrument.
§ “Capitalization” is a unique product with Brazilian insurers which combines savings with the National Lottery.
§ Bancassurance is the dominant distribution channel for individual life insurance, retirement savings, and capitalization products.

Key Issues & Facts

§ What are driving factors for the insurance industry (life and non-life insurance) in Brazil?
§ How is the growth in retirement savings and automobile insurance driving the insurance sector?
§ What are the emerging opportunities and challenges for the industry players?
§ What are the most prospective areas for investments in the insurance sector in near future?
§ Who are the key players in the Brazilian insurance market?

Research Methodology Used

Information Sources
Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear regression, analysis using software tools, judgmental forecasting and cause and effect analysis.

目录及图表

1. Analyst View
2. Global Clinical Trials Market
     2.1 What are Clinical Trials?
     2.2 Conducting Clinical Trials is becoming Costlier & Difficult
     2.3 Clinical Research Outsourcing Market
            2.3.1 North America
            2.3.2 Europe
            2.3.3 Latin America
            2.3.4 Africa
            2.3.5 Asia-Pacific
3. Indian Clinical Trials Market
     3.1 Why should Companies Conduct Clinical Trials in India?
            3.1.1 Access to a Large Patient Pool
            3.1.2 Lower Cost
            3.1.3 Faster Completion
            3.1.4 Improving Infrastructure & Large Pool of Healthcare Professionals
            3.1.5 English-based Medical Education & Documentation
            3.1.6 Lucrative Pharmaceutical Market
     3.2 Market Analysis
            3.2.1 Introduction
            3.2.2 Size & Availability of Patient Pool
                      3.2.2.1 Population & Demographics
                      3.2.2.2 Disease Profile
                      3.2.2.3 Patient Availability & Recruitment
            3.2.3 Regulatory Environment
                      3.2.3.1 Regulatory Affairs
                      3.2.3.2 The Institutional Ethics Committee (IEC)
                      3.2.3.3 Trials that can/cannot be Conducted in India
                      3.2.3.4 Clinical Trials Registry
                      3.2.3.5 Intellectual Property Protection
                      3.2.3.6 Incentives given by the Government
            3.2.4 Economic Analysis
                      3.2.4.1 Phase I Clinical Trials
                                   3.2.4.1.1 Cost of Staff
                                   3.2.4.1.2 Cost of Utility
                      3.2.4.2 Phase II Clinical Trials
                                   3.2.4.2.1 Cost of Infrastructure & Staff
                                   3.2.4.2.2 Cost of Utility
                      3.2.4.3 Phase III Clinical Trials
                                   3.2.4.3.1 Cost of Infrastructure & Staff
                                   3.2.4.3.2 Cost of Utility
                      3.2.4.4 Phase IV Clinical Trials
                                   3.2.4.4.1 Cost of Infrastructure & Staff
                                   3.2.4.4.2 Cost of Utility
            3.2.5 Infrastructure & Expertise
                      3.2.5.1 Education
                      3.2.5.2 Doctors & Nurses
                      3.2.5.3 Hospital Beds
                      3.2.5.4 ICH/GCP Compliant Sites
                      3.2.5.5 Trained Investigators
                      3.2.5.6 Clinical Data Management
                      3.2.5.7 High Rate of Clinical Trials
                      3.2.5.8 On-time Completion of Clinical Trials
            3.2.6 Opportunities
                      3.2.6.1 Strong Growth for Contract Research Organizations
                      3.2.6.2 Increased Demand for Clinical Research Professionals
                      3.2.6.3 Demand for Clinical Training Institutes
                      3.2.6.4 Pathology & Diagnostic Market
                      3.2.6.5 Clinical Data Management
                      3.2.6.6 Business Process Outsourcing
            3.2.7 Challenges
                      3.2.7.1 Ethical Issues
                      3.2.7.2 Lack of Trained Staff
                      3.2.7.3 Intellectual Property Protection
                      3.2.7.4 Long Time for Approval
                      3.2.7.5 Data Exclusivity
4. Key Players
     4.1 Quintiles Transnational Corp.
     4.2 Pfizer Inc.
     4.3 Roche Group
     4.4 Dr. Reddy's Laboratories Ltd.
     4.5 Sanofi-Aventis S.A.
     4.6 Ranbaxy Laboratories Ltd.
     4.7 GlaxoSmithKline plc
     4.8 Eli Lilly & Company
     4.9 Novo Nordisk A/S
     4.10 iGATE Clinical Research International
     4.11 ClinInvent Research Pvt. Ltd.
     4.12 Reliance Clinical Research Services Pvt. Ltd.
     4.13 SIRO Clinpharm Pvt. Ltd.

List of Figures:

Figure 2-1: Drug Discovery, Development & Approval Process
Figure 2-2: Cost of Developing a New Drug (in Million US$), 1979, 1991, 1995, 2001, 2003, 2006E & 2008E
Figure 2-3: Global - Pharma R&D Expenditure by Function (%), 2006
Figure 2-4: Global - Forecast for Pharma R&D Expenditure by Function (%), 2008
Figure 2-5: Global - Clinical Research Outsourcing Market (in Billion US$), 2005 & 2006
Figure 2-6: Global - Forecast for Clinical Research Outsourcing Market (in Billion US$), 2007-2011
Figure 2-7: Global - Clinical Research Outsourcing Market by Region (%), 2005E
Figure 3-1: India & US - Average Cost for Conducting Various Phases of Clinical Trials (in Million US$)
Figure 3-2: India & US - Time Taken for Conducting Clinical Trials by Phase (in Months)
Figure 3-3: India - Pharmaceutical Market (in Billion US$), 2005, 2006E & 2015E
Figure 3-4: India - Clinical Trials Market (in Million US$), 2002, 2005 & 2006
Figure 3-5: India - Forecast for Clinical Trials Market (in Million US$), 2007-2011
Figure 3-6: India - Population (in Million), 2003-2006E
Figure 3-7: India - Forecast for Population (in Million), 2007-2011
Figure 3-8: India - Gender Ratio (%), 2003-2006
Figure 3-9: India - Population Breakup by Age Group (%), 2003-2006E
Figure 3-10: India - Forecast for Population Breakup by Age Group (%), 2007-2011
Figure 3-11: India - Number of Deaths due to Various Causes, 2005
Figure 3-12: India - Various Causes of Death (%), 2005
Figure 3-13: India - Forecast for Various Causes of Death (%), 2030
Figure 3-14: India - New Cancers Incidences (per 100,000 Females), 2005E
Figure 3-15: India - New Cancers Incidences (per 100,000 Males), 2005E
Figure 3-16: India - Number of Deaths due to Various Cardiovascular Diseases (in ‘000), 2002
Figure 3-17: India - Number of Deaths due to Neuropsychiatry Conditions (in ‘000), 2002
Figure 3-18: South Africa, Nigeria & India - Number of HIV/AIDS Patients (in Million), 2007E
Figure 3-19: India - Number of Deaths due to Hepatitis B & C (in ‘000), 2002
Figure 3-20: India & US - Recruitment Time for Patients Participating in Clinical Trials (%)
Figure 3-21: India & US - Patient Concentration per Site (in Numbers)
Figure 3-22: India - Number of Patients Participating in Clinical Trials (2005 & 2006E)
Figure 3-23: India - Forecast for Number of Patients Participating in Clinical Trials (2007-2011)
Figure 3-24: India, UK, US & Germany - Average Cost per Patient for Conducting Clinical Trials (in US$)
Figure 3-25: India, UK, US & Germany - Average Cost per Patient for Conducting Phase I Clinical Trials (in US$)
Figure 3-26: India, UK, US & Germany - Average Cost per Patient for Conducting Phase II Clinical Trials (in US$)
Figure 3-27: India, UK, US & Germany - Annual Cost of Office Space for Conducting Phase II Clinical Trials (in US$)
Figure 3-28: India, UK, US & Germany - Average Cost per Patient for Conducting Phase III Clinical Trials (in US$)
Figure 3-29: India, UK, US & Germany - Annual Cost of Office Space for Conducting Phase III Clinical Trials (in US$)
Figure 3-30: India, UK, US, & Germany - Average Cost per Patient for Conducting Phase IV Clinical Trials (in US$)
Figure 3-31: India, UK, US & Germany - Annual Cost of Office Space for Conducting Phase IV Clinical Trials (in US$)
Figure 3-32: India - Number of Individuals with Bachelors & Higher Degree (in Million), 1991, 2004 & 2006E
Figure 3-33: India - Number of Graduates & Postgraduates (in Million), 2004
Figure 3-34: India - Science Doctorates as a Percentage of Total Doctorates, 2004
Figure 3-35: India - Structure of Medical Education, 2005
Figure 3-36: US, India & Germany - Number of Doctors (in ‘000), 2006E
Figure 3-37: India - Number of Doctors (in ‘000), 2005 & 2006E
Figure 3-38: India - Forecast for Number of Doctors (in ‘000), 2007-2011
Figure 3-39: US, India & UK - Number of Nurses (in ‘000), 2005E
Figure 3-40: India - Number of Nurses (in ‘000), 2004-2006E
Figure 3-41: India - Forecast for Number of Nurses (in ‘000), 2007-2011
Figure 3-42: India, UK, US & Germany - Number of Hospital Beds (in ‘000), 2006E
Figure 3-43: India - Number of Hospital Beds (in ‘000), 2004-2006E
Figure 3-44: India - Forecast for Number of Hospital Beds (in ‘000), 2007-2011
Figure 3-45: India, UK, US & Germany - Number of Sites for Clinical Trials
Figure 3-46: India - Number GCP Trained Investigators (2002 & 2005)
Figure 3-47: India & US - Number of GCP Trained Investigators, 2005
Figure 3-48: Global - Number of Clinical Trials (2005 & 2006E)
Figure 3-49: Global - Forecast for Number of Clinical Trials (2007-2011)
Figure 3-50: India - Number of Clinical Trials (2005 & 2006E)
Figure 3-51: India - Forecast for Number of Clinical Trials (2007-2011)
Figure 3-52: India, UK, US & Germany - Percentage of Clinical Trials Completed on Time
Figure 3-53: India - CRO Market (in Million US$), 2006 & 2010F
Figure 3-54: India - Staff Requirement for Conducting Clinical Trials (in Numbers), 2003, 2008F & 2010F
Figure 3-55: India - Pathology Market (in Million US$), 2003-2006E
Figure 3-56: India - IVD Market (in Million US$), 2006 & 2010F
Figure 3-57: India, UK, US & Germany - Average Time for Approval of Clinical Trials (in Weeks)

List of Tables:

Table 2-1: Global - R&D Spending (in Million US$) & Number of Clinical Trials Conducted by Top Pharmaceutical  Companies, 2005
Table 2-2: North America - Characteristics of Clinical Research Outsourcing Market, 2005
Table 2-3: Europe - Characteristics of Clinical Research Outsourcing Market, 2005
Table 2-4: Latin America - Characteristics of Clinical Research Outsourcing Market, 2005
Table 2-5: Africa - Characteristics of Clinical Research Outsourcing Market, 2005
Table 2-6: Asia-Pacific - Characteristics of Clinical Research Outsourcing Market, 2005
Table 3-1: India & US - Annual Salaries of Clinical Research Professionals (in US$)
Table 3-2: India - Number of Diabetic Patients in Age Group 20-79 (in ‘000), 2003
Table 3-3: India - Forecast for Number of Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 3-4: India, UK, US & Germany - Annual Cost of Staff for Conducting Phase I Clinical Trials (in US$)
Table 3-5: India, UK, US & Germany - Annual Cost of Utility for Conducting Phase I Clinical Trials (in US$)
Table 3-6: India, UK, US & Germany - Annual Cost of Staff for Conducting Phase II Clinical Trials (in US$)
Table 3-7: India, UK, US & Germany - Annual Cost of Utility for Conducting Phase II Clinical Trials (in US$)
Table 3-8: India, UK, US & Germany - Annual Cost of Staff for Conducting Phase III Clinical Trials (in US$)
Table 3-9: India, UK, US & Germany - Annual Cost of Utility for Conducting Phase III Clinical Trials (in US$)
Table 3-10: India, UK, US & Germany - Annual Cost of Staff for Conducting Phase IV Clinical Trials (in US$)
Table 3-11: India, UK, US & Germany - Annual Cost of Utility for Conducting Phase IV Clinical Trials (in US$)
Table 4-1: Quintiles Transnational Corp. - Key Financials (in Million US$), 2003-2005
Table 4-2: Pfizer Inc. - Key Financials (in Million US$), 2004-2006
Table 4-3: Roche Group - Key Financials (in Million CHF), 2004-2006
Table 4-4: Dr. Reddy's Laboratories Ltd. - Key Financials (in Million US$), 2004-2006
Table 4-5: Sanofi-Aventis S.A. - Key Financials (in Million US$), 2004-2006
Table 4-6: Ranbaxy Laboratories Ltd. - Key Financials (in Million US$), 2005 & 2006
Table 4-7: GlaxoSmithKline plc - Key Financials (in Million US$), 2004-2006
Table 4-8: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
Table 4-9: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
Table 4-10: iGATE Clinical Research International - Key Financials (in Million INR), 2005 & 2006